Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide in Xeroderma Pigmentosum (XP-C)
NCT05159752Phase 2Unknown
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Afamelanotide in xeroderma pigmentosum (XP), sponsored by Clinuvel Pharmaceuticals. Status: unknown.
02
Drugs
Afamelanotide
03
Conditions
xeroderma pigmentosum (XP)
Beyond the preview
Go deeper on NCT05159752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159752.